Abstract
Introduction: Ovarian cancer stands as the predominant gynecological malignancy on a global scale a global gynecological malignancy with a >60% mortality rate, often necessitates aggressive surgeries like maximal cytoreduction to enhance survival. However, these procedures pose bleeding risks requiring blood transfusions. Tranexamic acid (TXA), a longestablished clotting inhibitor, offers potential solutions. Our objective is to assess TXA's safety and efficacy in minimizing perioperative bleeding during ovarian cancer surgery through a thorough literature review .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
